Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 11Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Mantle-Cell 5Lymphoma, Non-Hodgkin 4Waldenstrom Macroglobulinemia 2Neoplasms 2Lymphoma 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Leukemia, B-Cell 1Leukemia 1Head and Neck Neoplasms 1Anemia 1

Interventions

ibrutinib 1fludarabine phosphate 1Rituximab 1Pharmacogenomic Testing 1Lenalidomide 1Epoetin Alfa 1Cyclophosphamide 1CT-P10 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia × ibrutinib × 30 days × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡